| Literature DB >> 30214718 |
Jannicke Slettli Wathne1,2,3, Lars Kåre Selland Kleppe4, Stig Harthug1,2, Hege Salvesen Blix5, Roy M Nilsen6, Esmita Charani7, Ingrid Smith8.
Abstract
Background: There is limited evidence from multicenter, randomized controlled studies to inform planning and implementation of antibiotic stewardship interventions in hospitals.Entities:
Keywords: Academic detailing; Antibiotic stewardship; Audit with feedback; Goal setting; Hospital; Intervention; cRCT
Mesh:
Substances:
Year: 2018 PMID: 30214718 PMCID: PMC6131848 DOI: 10.1186/s13756-018-0400-7
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Overview of implemented interventions
| Intervention | Hospital | Specialty | Intervention sessions | Attendance consultants/ residents (estimated) | Performed by | Special features of each intervention | Common features of intervention sessions for both audit with feedback and academic detailing |
|---|---|---|---|---|---|---|---|
| Audit with feedback | A | Pulmonary medicine | 16.05.14 | 70% | Local pharmacist + study ward consultant | Focus areas: | 1. Verbal presentation including: |
| B | Infectious diseases | 20.05.14 | 100% | ||||
| Academic detailing | A | Gastro-enterology | 14.05.14 | 90% | Local ID-physician | Case discussions on recently discharged patients with infectious diseases. | |
| B | Pulmonary medicine | 13.05.14 | 100% | ||||
| C | Infectious diseases | 20.05.14 | 70% | ||||
| Control | A | Infectious diseases | |||||
| B | Gastro-enterology | ||||||
| C | Pulmonary medicine | ||||||
Patient characteristics and patient outcome pre- and post-implementation of interventions, per intervention group and specialty
| Pulmonary medicine Period | Infectious diseases Period | Gastroenterology Period | Audit with feedback Period | Academic detailing Period | Control (all three specialities) Period | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | |||||||
| Age (mean - years) | 69.6 | 68.99 | 0.66 | 67.5 | 64.4 | 0.10 | 68.9 | 64.8 | 0.35 | 67.1 | 66.1 | 0.51 | 70.2 | 67.1 | 0.05 | 63.2 | 65.7 | 0.22 |
| Sex | ||||||||||||||||||
| Female | 213 (49.9) | 88 (54.3) | 0.34 | 180 (42.5) | 80 (52.3) |
| 37 (47.4) | 16 (41.0) | 0.51 | 221 (46.2) | 101 (55.5) |
| 209 (46.3) | 83 (48.3) | 0.67 | 167 (47.7) | 80 (47.3) | 0.94 |
| Male | 214 (50.1) | 74 (45.7) | 244 (57.5) | 73 (47.7) | 41 (52.6) | 23 (59) | 257 (53.8) | 81 (44.5) | 242 (53.7) | 89 (51.7) | 183 (52.3) | 89 (52.7) | ||||||
| Admitted from hospital/nursing home | 55 (12.9) | 15 (9.3) | 0.23 | 68 (16.0) | 30 (19.7) | 0.30 | 14 (18.0) | 3 (7.7) | 0.14 | 67 (14.0) | 20 (11.0) | 0.30 | 70 (15.5) | 28 (16.4) | 0.79 | 51 (14.6) | 23 (13.6) | 0.75 |
| Indication for antibiotic treatment | ||||||||||||||||||
| Pneumonia | 136 (31.9) | 63 (38.9) | 0.20 | 115 (27.1) | 45 (29.6) | 0.06 | 11 (14.1) | 3 (7.7) | 0.16 | 162 (33.9) | 67 (36.8) |
| 100 (22.2) | 44 (25.7) | 0.15 | 65 (18.7) | 23 (13.6) | 0.31 |
| COPD exacerbation, infectious | 183 (42.9) | 63 (38.9) | 59 (13.9) | 7 (4.6) | 1 (1.3) | 2 (5.1) | 132 (27.6) | 34 (18.7) | 111 (24.6) | 38 (22.2) | 25 (7.2) | 15 (8.9) | ||||||
| LRTI - Other | 23 (5.4) | 9 (5.6) | 16 (3.7) | 6 (3.95) | 6 (7.7) | 2 (5.1) | 19 (4.0) | 4 (2.2) | 26 (5.8) | 13 (7.6) | 22 (6.3) | 7 (4.1) | ||||||
| Sepsis | 40 (9.4) | 17 (10.5) | 61 (14.4) | 24 (15.8) | 16 (20.5) | 5 (12.8) | 57 (11.9) | 26 (14.3) | 60 (13.3) | 20 (11.7) | 73 (21.0) | 50 (29.6) | ||||||
| Skin and soft tissue | 3 (0.7) | 2 (1.2) | 62 (14.6) | 33 (21.7) | 9 (11.5) | 6 (15.4) | 31 (6.5) | 25 (13.7) | 43 (9.5) | 16 (9.4) | 58 (16.7) | 22 (13.0) | ||||||
| Gastrointestinal tract | 1 (0.2) | 0 (0) | 9 (2.12) | 4 (2.6) | 9 (11.5) | 11 (28.2) | 6 (1.3) | 2 (1.1) | 13 (2.8) | 13 (7.6) | 35 (10.1) | 14 (8.3) | ||||||
| Urinary tract | 9 (2.1) | 5 (3.1) | 75 (17.7) | 21 (13.8) | 17 (21.8) | 9 (23.1) | 31 (6.5) | 16 (8.8) | 70 (15.5) | 19 (11.1) | 36 (10.3) | 19 (11.2) | ||||||
| Other | 32 (7.5) | 3 (1.9) | 27 (6.4) | 12 (7.9) | 9 (11.5) | 1 (2.6) | 40 (8.4) | 8 (4.4) | 28 (6.2) | 8 (4.7) | 34 (9.8) | 19 (11.2) | ||||||
| Antibiotic allergies | 62 (14.5) | 28 (17.3) | 0.41 | 35 (8.3) | 19 (12.4) | 0.13 | 8 (10.3) | 4 (10.3) | 0.99 | 59 (12.3) | 26 (14.3) | 0.51 | 46 (10.2) | 25 (14.5) | 0.13 | 25 (7.2) | 17 (10.1) | 0.18 |
| Patient outcomes ∆ | ||||||||||||||||||
| Length of stay (days) | 7.2 | 6.9 | 0.40 | 6.5 | 6.5 | 0.99 | 7.0 | 6.1 | 0.30 | 7.2 | 6.5 |
| 6.5 | 6.8 | 0.41 | 7.5 | 6.8 | 0.11 |
| In-hospital mortality | 30 (7.0) | 7 (4.3) | 0.23 | 12 (2.8) | 4 (2.61) | 0.89 | 3 (3.9) | 2 (5.13) | 0.76 | 28 (5.9) | 9 (5.0) | 0.65 | 17 (3.8) | 4 (2.3) | 0.37 | 13 (3.7) | 3 (1.8) | 0.23 |
| 30-day mortality | 53 (12.4) | 11 (6.8) | 0.05 | 30 (7.1) | 8 (5.3) | 0.44 | 3 (3.9) | 4 (10.3) | 0.17 | 50 (10.5) | 12 (6.6) | 0.13 | 36 (8.0) | 11 (6.4) | 0.51 | 24 (6.9) | 6 (3.6) | 0.13 |
| 30-day readmission | 117 (29.3) | 38 (24.5) | 0.26 | 78 (19.1) | 18 (12.2) | 0.06 | 16 (21.3) | 6 (17.1) | 0.61 | 111 (24.6) | 36 (20.9) | 0.33 | 100 (23.1) | 26 (15.7) |
| 58 (17.5) | 30 (18.6) | 0.75 |
p-values are obtained by chi-square test (categorical variables) and t-test (continuous variables) per group
∆ Patient outcomes were also tested for interaction between intervention groups/specialty and period using linear and logistic regression. p-value interaction length of stay = 0.080. p-value interaction 30-day readmission = 0.105
Percentage of adherence to antibiotic guidelines in periods before and after interventions were implemented
| Group | Group description | N Before/after | Period | Absolute Change % | P for changea | P for Interactionb | |
|---|---|---|---|---|---|---|---|
| Before n (%) | After n (%) | ||||||
| Intervention | |||||||
| Control | All specialties | 350/169 | 174 (50) | 84 (50) | 0 | 0.998 | |
| Interventions | All specialties | 929/354 | 556 (60) | 234 (66) | 6 |
| 0.252 |
| Academic detailing | All specialties | 451/172 | 265 (59) | 111 (65) | 6 | 0.188 | 0.353 |
| Audit with feedback | Infectious diseases + Pulmonary medicine | 478/182 | 291 (61) | 123 (68) | 7 | 0.111 | 0.265 |
| Specialty | |||||||
| Pulmonary medicine | Both interventions | 427/162 | 249 (58) | 116 (72) | 14 |
|
|
| Infectious diseases | Both interventions | 424/153 | 268 (63) | 99 (65) | 2 | 0.741 | 0.857 |
| Gastroenterology | Academic detailing | 78/39 | 39 (50) | 19 (49) | -1 | 0.896 | 0.556 |
aBy chi-square test per group
bBy logistic regression of given group vs control wards (all specialties), giving the p-value for the interaction between group and period
P-values < 0.05 are given in boldface
Local targets set by study intervention wards and outcome for targeted change in prescribing practice
| Hospital | Ward | Intervention | Targets | Outcome |
|---|---|---|---|---|
| A | Pulmonary medicine | Audit with feedback | Increase the use of Penicillin G 2 mill IU × 4 to treat pneumonia (CAP) and infectious COPD exacerbations | 30% increase ( |
| A | Gastroenterology | Academic detailing | Reduce ciprofloxacin use for inflammatory bowel disease, and shift to Co-trimoxazol | Too few patients with targeted indication to assess outcome by indication. |
| B | Pulmonary medicine | Academic detailing | Target areas discussed: |
|
| B | Infectious diseases | Audit with feedback | Target areas discussed: |
|
| C | Infectious diseases | Academic detailing |
|
|
aBy chi-square test bBy Interrupted time series analysis (Appendix Table 6)
Interrupted time series analysis of the use of broad-spectrum antibiotics in defined daily doses per 100 bed days for intervention and control groups from 2013 to 2015
| Audit with feedback (Intervention wards) | Academic detailing (Intervention wards | Pulmonary medicine (Intervention wards) | Infectious diseases (Intervention wards) | Gastroenterology (Intervention ward) | Control (all specialties) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | ||||||||
| DDD per 100 bed days | Const | 70.288 | 5.854 | 0.000 | 103.078 | 8.415 | 0.000 | 84.736 | 5.056 | 0.000 | 60.371 | 7.407 | 0.000 | 27.605 | 1.592 | 0.000 | 87.691 | 5.387 | 0.000 |
| AR | −0.495 | 0.326 | 0.172 | −0.247 | 0.370 | 0.525 | −0.429 | 0.348 | 0.257 | −0.239 | 0.372 | 0.542 | −0.796 | 0.203 | 0.006 | −0.512 | 0.323 | 0.157 | |
| Pre-slope | 4.332 | 1.523 |
| −2.903 | 2.181 | 0.225 | −2.292 | 1.312 | 0.124 | 3.985 | 1.926 | 0.077 | −0.075 | 0.411 | 0.861 | 1.002 | 1.404 | 0.498 | |
| Difference between pre- and post-slope | −6.789 | 2.028 |
| 2.920 | 2.985 | 0.360 | −0.669 | 1.770 | 0.717 | −5.753 | 2.615 | 0.064 | 2.472 | 0.545 |
| −1.033 | 1.863 | 0.597 | |
| Level effect | |||||||||||||||||||
| 3 months | −8.971 | 7.809 | 0.288 | −3.162 | 11.053 | 0.783 | 8.314 | 6.686 | 0.254 | −10.360 | 9.839 | 0.327 | −11.157 | 2.082 |
| 1.407 | 7.191 | 0.850 | |
| 6 months | −15.761 | 8.313 | 0.100 | −0.242 | 11.823 | 0.984 | 7.646 | 7.131 | 0.319 | −16.112 | 10.503 | 0.169 | −8.685 | 2.220 |
| 0.374 | 7.672 | 0.962 | |
| 12 months | −29.338 | 10.490 |
| 5.599 | 15.115 | 0.722 | 6.308 | 9.052 | 0.508 | −27.617 | 13.357 | 0.077 | −3.740 | 2.811 | 0.225 | −1.691 | 9.694 | 0.866 | |
| 18 months | −42.916 | 13.561 |
| 11.439 | 19.708 | 0.580 | 4.971 | 11.751 | 0.685 | −39.122 | 17.355 | 0.059 | 1.205 | 3.640 | 0.750 | −3.757 | 12.525 | 0.773 | |
Broad-spectrum antibiotics were defined as penicillins with enzyme inhibitor, 2. and 3. generation cephalosporins, carbapenems and quionolones
Interrupted Time Series analysis of the use of Ciprofloxacin at the ward of Gastroenterology, Hospital A, from 2013 to 2015
| Estimate | SE | |||
|---|---|---|---|---|
| Ciprofloxacin DDD per 100 bed days | Constant | 10.291 | 1.283 | 0.000 |
| AR | −0.090 | 0.520 | 0.868 | |
| Pre-slope | −0.169 | 0.341 | 0.636 | |
| Difference between pre- and post-slope | −0.106 | 0.461 | 0.825 | |
| Level effect | ||||
| 3 months | −4.254 | 1.905 | 0.061 | |
| 6 months | −4.360 | 1.956 | 0.061 | |
| 12 months | −4.571 | 2.343 | 0.092 | |
| 18 months | −4.783 | 2.975 | 0.152 | |
Use of Ciprofloxacin is measured as quarterly sales of Ciprofloxacin, adjusted for bed days